Contact Us

Contact us with any questions or comments regarding our novel approach to treating infectious, inflammatory, and degenerative diseases with our plasma gelsolin technology platform.

Name

Phone

Organization

Role

Scientist/Academic Media Investor Other

Message

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

Clinical Trials Arena Award -
Best Covid 19 Response
February 2021

January 2023: BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’ Gelsolin, for the Treatment of ARDS

January 26, 2023

January 2023: BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases

January 6, 2023

March 2022: BioAegis Therapeutics Completes $22 Million Institutional Sale of Equity in a Non-Brokered Transaction

March 22, 2022

November 12, 2021: Belgium MACRO Trends Investors Conference

October 6-7, 2020: BioNJ’s 10th Annual BioPartnering Conference

Tweets by BioAegis

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

PRODUCT FAQS

Twitter Linkedin Youtube Medium

Contact Us

Stay informed of our latest discoveries and news.

COMPANY DETAILS

FOLLOW US